AI-Powered Molecular Dynamics Drug Discovery Firm Yulu Qianxing Completes Series B Financing Led by Fosun Pharma's Fosun Jian Suzhou Angel Fund

VCBeat learned第一时间 that Divamics Inc. (hereinafter referred to as "Divamics") has recently completed its second round of financing.This round of financing was led by Fosun Pharma's Fosun Jianxin Suzhou Fund and followed by China-Singapore Capital.The funds raised will be mainly used for the investment in the company's new generation of artificial intelligence drug research and development platform, database construction, as well as the continued expansion of domestic and international drug co-research markets, helping to explore the pipeline value of various difficult-to-drug targets.

Divamics is a new drug molecule discovery factory based on DBDD (Dynamics-based Drug Discovery), focusing on the early stage of drug development and providing new drug discovery CRO services to innovative pharmaceutical companies.Divamics Inc. was awarded the title of a leading technology project enterprise in Suzhou Industrial Park at its inception, and in 2022, it was approved for the municipal-level Gusu Leading Talent Project in Suzhou. Its core technology is multi-scale molecular dynamics (MD) based on AI force fields, capable of simulating dynamic changes in protein structures and drug target binding modes ranging from tens of nanoseconds to milliseconds. This enables highly flexible target modeling, target druggability analysis, structure screening, design, and optimization for small molecule/PROTAC/antibody drugs.

Protein Activation Process under Multi-scale Molecular Dynamics Simulation

Molecular dynamics simulations play a crucial role in the AI pharmaceuticals field, providing comprehensive dynamic mechanism information. Currently, about 85% of "hard-to-drug" targets are due to the missing information between structural data and motion patterns, making it difficult for human experience alone to predict accurately. The application of AI + molecular dynamics in drug discovery is rewriting the history of "undruggable" targets. Divamics' multi-scale molecular dynamics can more precisely locate binding sites while integrating virtual screening to improve the hit rate of new drug molecules.

Divamics' core technology has been recommended by Nobel Prize in Chemistry laureate Roald Hoffman and is increasingly trusted and recognized by more new drug research and development clients. Currently, it has collaborated with multiple domestic and international biopharmaceutical companies to advance over 15 new drug R&D pipelines, achieving several breakthrough results. Collaborative clients include Ansstone Biotech, RayChew Pharmaceuticals, Guangdong Provincial People's Hospital, as well as listed companies and multinational biotechs, reaching several milestones in areas such as AI + difficult drug targets and AI + PROTAC.

Divamics CEO Zheng Zhen stated:Enterprise development cannot be achieved without the favor of investors and the attention of the market. We are very pleased to have established a cooperative relationship with strategic investors such as Fosun and Sino-Singapore Capital this time, and we also thank all our new and existing shareholders for their recognition of our company’s commercial positioning, R&D layout, and development strategy. In the future, Divamics will focus more on the integration of technology in computer science and new drug R&D, fully leveraging the technical advantages of multi-scale molecular dynamics interpretive models. Based on the characteristics of various targets and different drugs, Divamics will provide drug R&D teams with clearer and more comprehensive information on molecular drug mechanisms. Meanwhile, Divamics will use this round of financing to rapidly expand its domestic and international drug co-development markets, collaborating with more customers across various fields of drug R&D to accelerate the early-stage drug discovery process. Special emphasis will be placed on exploring the pipeline value of various difficult-to-drug targets.

Li Jiaxin, General Manager of Fosun Pharma Fosun Health Capital Suzhou Angel Fund, stated:Divamics, with its distinctive molecular dynamics simulation algorithm platform and profound understanding of protein structure and spatial movement, has addressed some of the challenges and difficulties faced by artificial intelligence in new drug development to a certain extent. It provides new strategies and solutions for the drug development of difficult-to-drug targets for partner companies and has received unanimous praise from them. We are delighted to be part of this, supporting enterprise growth, and believe that under the leadership of Dr. Zheng Zheng, Divamics will further enhance its diversified, high-barrier service capabilities in the vertical field, becoming one of the leading enterprises in China's AI-empowered new drug development sector.

Tian Xueling, Chairman of Zhongxin Capital, said:The application of digitalization and AI assistance in various industries is becoming increasingly profound, and the value it demonstrates is obvious. In the field of new drug research and development, AIDD is full of opportunities but also faces many challenges. Encouragingly, we see that Divamics' multi-scale molecular dynamics technology has solved the pain point of only being able to parse static protein images under the existing AIDD model, significantly improving the success rate of R&D, especially for difficult drug targets. This helps shorten the R&D cycle and reduce costs. We are very pleased to participate in this investment, hoping that with the help of Divamics, more new drugs can be launched earlier to benefit a large number of patients.

About Rehabilitation Capital

Fujian Capital (Shanghai Fujian Equity Investment Fund Management Co., Ltd.) is a holding subsidiary established by Fosun Pharma and serves as its fund management company. Leveraging Fosun Pharma's over 20 years of accumulated advantages in the biopharmaceutical industry, as well as Fosun's experience in collaborating with top-tier domestic and international funds and companies, Fujian Capital focuses on the entrusted management of funds in the broader healthcare sector. Fujian Capital manages multiple RMB funds, concentrating on investments in the medical and healthcare field, with a management scale nearing 5 billion yuan. Its primary investments span various subfields of healthcare, including biomedicine, high-end medical devices, in vitro diagnostics, life sciences, and treatment technologies, utilizing diverse exit strategies to achieve capital appreciation. By synergizing with Fosun’s global R&D strengths and industrial layout, Fujian Capital empowers invested enterprises throughout their entire lifecycle, driving business growth.

About Sino Capital

Zhongxin Capital, a professional fund manager under Zhongxin Group, actively engages in venture capital activities through its Yuanchuang and Yuanzhan series of funds. Based in Suzhou Industrial Park, with a focus on various cooperation zones within the Zhongxin system, and extending to the China-Singapore International Business Cooperation Center (offshore), it centers around regional leading and advantageous industries. It emphasizes empowering the industrialization and internationalization of "specialized, refined, distinctive, and innovative" enterprises.